Peter DR Higgins, MD, PhD, MSc(CRDSA), AGAF
Manage Your Profile
About
Dr. Peter Higgins received his bachelor's degree and medical degrees from Duke University, and completed a Ph.D. in molecular cancer biology at Duke. He completed a fellowship in gastroenterology at the University of Michigan in 2004, completed an M.Sc. in Clinical Research Design and Statistical Analysis at the University of Michigan School of Public Health, and joined the University of Michigan faculty the same year. Dr. Higgins has previously served as the IBD editor for the American Journal of Gastroenterology, the chair of the AGA Immunology, Microbiology, and IBD section, and chaired the University of Michigan GI Division Research Advisory Council. His research focuses on inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. He is interested in the molecular mechanisms of intestinal fibrosis, which leads to intestinal blockages and surgery. Dr. Higgins studies novel approaches to Acute Severe Ulcerative Colitis and strictures in Crohn's disease. His clinical research includes studies on patient-reported outcomes in IBD, cell therapies in IBD, and biomarker-guided therapy in IBD. Dr. Higgins' research interests are complemented by his clinical interest in improving the quality of care of patients with IBD. He served as a member of the AGA IBD Quality Measures Committee, and has participated in the development of national guidelines for high quality IBD care. Dr. Higgins currently serves as the NSAC (National Scientific Advisory Committee) chair of the Crohn's and Colitis Foundation. Dr. Higgins has received many honors and awards, including the AGA IBD Clinical Research Excellence Award.
Links
Higgins IBD Program
Center Memberships
-
Center MemberAI and Digital Health Innovation
Research Overview
Detection and measurement of inflammation in inflammatory bowel disease (IBD). Mechanisms of intestinal fibrosis, and measurement of fibrosis with ultrasound and biomarkers. Development of novel anti-fibrotic and anti-inflammatory therapies. Patient-reported outcomes in IBD.
Recent Publications
-
Newman KL, Standke AK, James G, Vendrov KC, Inohara N, Bergin IL, Higgins PDR, Rao K, Young VB, Kamada N. Gut Microbes, 2026 Dec 31; 18 (1): 2604875Journal ArticleMiniature bioreactor arrays for modeling functional and structural dysbiosis in inflammatory bowel disease
DOI:10.1080/19490976.2025.2604875 PMID: 41427586 -
Wilcox S, Herran R, Ardente L, Shah AM, Hassan SA, Hodish G, Palazzolo B, Gu P, Tedesco NR, Goyal MK, Bishu S, Cohen-Mekelburg S, Regal R, Higgins PD, Kayal M, Berinstein J. Gastrointestinal Endoscopy, 2026 May 6; 103 (5): s-1179-s-1180Journal ArticleMo1543 COMPARATIVE EFFECTIVENESS OF TOFACITINIB AND UPADACITINIB FOR PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS: A MULTICENTER UNITED STATES EXPERIENCE
DOI:10.1016/s0016-5107(26)02913-5 -
Wilcox S, Herran R, Ardente L, Shah AM, Hassan SA, Hodish G, Palazzolo B, Gu P, Tedesco NR, Goyal MK, Bishu S, Cohen-Mekelburg S, Regal R, Higgins PD, Kayal M, Berinstein J. Gastroenterology, 2026 May 7; 170 (6): s-1179-s-1180Journal ArticleMo1543 COMPARATIVE EFFECTIVENESS OF TOFACITINIB AND UPADACITINIB FOR PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS: A MULTICENTER UNITED STATES EXPERIENCE
DOI:10.1016/s0016-5085(26)02982-3 -
Hill J, Ball S, Gjoka I, Wang Y-P, Gao J, Hassan SA, Young V, Berinstein J, Nojkov B, Chey W, Higgins PD, Rao K, Singh P, Bishu S, Lee A. Gastrointestinal Endoscopy, 2026 May 6; 103 (5): s-1209-s-1210Journal ArticleMo1607 FEASIBILITY AND EFFECTIVENESS OF A LOW-SULFUR DIET FOR THE MANAGEMENT OF QUIESCENT CROHN’S DISEASE WITH PERSISTENT GASTROINTESTINAL SYMPTOMS: RESULTS FROM A PILOT, CONTROLLED, STUDY
DOI:10.1016/s0016-5107(26)02977-9 -
Hill J, Ball S, Gjoka I, Wang Y-P, Gao J, Hassan SA, Young V, Berinstein J, Nojkov B, Chey W, Higgins PD, Rao K, Singh P, Bishu S, Lee A. Gastroenterology, 2026 May 7; 170 (6): s-1209-s-1210Journal ArticleMo1607 FEASIBILITY AND EFFECTIVENESS OF A LOW-SULFUR DIET FOR THE MANAGEMENT OF QUIESCENT CROHN’S DISEASE WITH PERSISTENT GASTROINTESTINAL SYMPTOMS: RESULTS FROM A PILOT, CONTROLLED, STUDY
DOI:10.1016/s0016-5085(26)03046-5 -
Hodish G, Sturgeon J, Berinstein J, DeJonckheere M, Galicia F, Sheehan JL, Kenney B, Waljee AK, Liran O, Higgins PD, Cohen-Mekelburg S. Gastrointestinal Endoscopy, 2026 May 6; 103 (5): s-1228-s-1229Proceeding / Abstract / PosterMo1652 OUTPATIENT VIRTUAL REALITY-DIRECTED TREATMENT FOR INFLAMMATORY BOWEL DISEASE-RELATED PAIN: A PILOT TRIAL
DOI:10.1016/s0016-5107(26)03022-1 -
Hodish G, Sturgeon J, Berinstein J, DeJonckheere M, Galicia F, Sheehan JL, Kenney B, Waljee AK, Liran O, Higgins PD, Cohen-Mekelburg S. Gastroenterology, 2026 May 7; 170 (6): s-1228-s-1229Proceeding / Abstract / PosterMo1652 OUTPATIENT VIRTUAL REALITY-DIRECTED TREATMENT FOR INFLAMMATORY BOWEL DISEASE-RELATED PAIN: A PILOT TRIAL
DOI:10.1016/s0016-5085(26)03091-x -
Feng Y, Johnson L, Lee Y, Cantwell MT, Shah YM, Higgins PD. Gastrointestinal Endoscopy, 2026 May 6; 103 (5): s-936-s-937Journal ArticleSa1451 THE NEW COMBINATION THERAPY: BARRIER-ENHANCING THERAPY WITH VADADUSTAT CLOSES THE THERAPEUTIC GAP OF ANTI-INFLAMMATORY THERAPY WITH UPADACITINIB IN DEXTRAN SULFATE SODIUM (DSS) COLITIS
DOI:10.1016/s0016-5107(26)02394-1
Featured News & Stories